Balaxi Pharmaceuticals Limited (NSE:BALAXI)
43.04
-0.24 (-0.55%)
Oct 24, 2025, 12:26 PM IST
Balaxi Pharmaceuticals Revenue
Balaxi Pharmaceuticals had revenue of 707.42M INR in the quarter ending June 30, 2025, with 7.80% growth. This brings the company's revenue in the last twelve months to 2.98B, up 23.54% year-over-year. In the fiscal year ending March 31, 2025, Balaxi Pharmaceuticals had annual revenue of 2.93B with 21.25% growth.
Revenue (ttm)
2.98B
Revenue Growth
+23.54%
P/S Ratio
0.80
Revenue / Employee
4.96M
Employees
600
Market Cap
2.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 2.93B | 512.67M | 21.25% |
| Mar 31, 2024 | 2.41B | -951.38M | -28.28% |
| Mar 31, 2023 | 3.36B | 570.45M | 20.42% |
| Mar 31, 2022 | 2.79B | 480.55M | 20.77% |
| Mar 31, 2021 | 2.31B | 1.86B | 406.95% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Aurobindo Pharma | 320.25B |
| Cipla | 274.80B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |